TranspireBio CEO Presents Industry View on FDA Bioequivalence Framework

TranspireBio Holdings Inc. CEO Xian-Ming Zeng presented the company's industry perspective on the U.S. Food and Drug Administration's (FDA) updated bioequivalence framework for inhalation drugs. The presentation was given at a workshop co-hosted by the FDA and the Center for Research on Complex Generics (CRCG) in Maryland on October 14–15, 2026.

The workshop, focused on advancing bioequivalence methods, allowed Zeng to discuss industry viewpoints on the FDA's evolving guidance. He addressed opportunities, challenges, and practical considerations for implementing innovative approaches that could facilitate the development of high-quality inhalation therapies.

TranspireBio is a clinical-stage biopharmaceutical company focused on inhaled therapeutics for respiratory and systemic diseases. The company leverages its proprietary technology platforms, including dry powder and soft mist inhalers, for developing treatments for conditions such as idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and central nervous system disorders.

Participation in the FDA and CRCG workshop highlights the company's role in industry advancements and its engagement with regulatory bodies. Dr. Zeng stated that the workshop's focus on innovative methods has the potential to translate rigorous science into more efficient development pathways, ultimately broadening patient access to quality inhaled medicines.